West Nile virus (WNV) non-structural protein 1 (NS1) elicits protective immune responses during infection of animals. WNV NS1-specific antibody responses can provide the basis for serological diagnostic reagents, so the antigenic sites in NS1 that are targeted by host immune responses need to be identified and the conservation of these sites among the Japanese encephalitis virus (JEV) serocomplex members also needs to be defined. The present study describes the mapping of linear B-cell epitopes in WNV NS1. We screened eight NS1-specific mAbs and antisera (polyclonal antibodies; pAbs) from mice immunized with recombinant NS1 for reactivity against 35 partially overlapping peptides covering the entire WNV NS1. The screen using mAbs identified four WNV-specific (including Kunjin virus) epitopes, located at aa 21-36, 101-116, 191-206 and 261-276 in WNV NS1. However, using pAbs, only three WNV-specific epitopes were identified, located at positions 101-116, 191-206 and 231-246. Two of these epitopes (aa 21-36 and 261-276) had different reactivity with mAbs and pAbs. The knowledge and reagents generated in this study have potential applications in differential diagnostics and epitope-based marker vaccine development for WNV and viruses of the JEV serocomplex.
INTRODUCTION
West Nile virus (WNV) is a medically important, mosquitoborne pathogen that is prevalent in Africa, Europe, Russia, the Middle East, India, Australia and North America (Garmendia et al., 2001) . WNV is classified serologically into the Japanese encephalitis virus (JEV) serocomplex, which includes WNV, JEV, Saint Louis encephalitis virus (SLEV) and Murray Valley encephalitis virus (MVEV) (Heinz et al., 2000; Weissenböck et al., 2002) .
The 10.7 kb WNV genome is translated into a single polyprotein, which is subsequently cleaved into three structural proteins (C, prM/M and E) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) by virus-and host-encoded proteases. NS1 is a highly conserved 48 kDa glycoprotein containing 12 invariant cysteine residues. It is inserted into the lumen of the endoplasmic reticulum via a signal peptide that is cleaved co-translationally by a cellular signalase to generate the mature N terminus of the protein (Chambers et al., 1990) . Within infected cells, NS1 is believed to function as a cofactor in viral RNA replication, and specific amino acid substitutions in NS1 attenuate viral RNA accumulation (Lindenbach & Rice, 1997) . In vivo, high levels of circulating dengue virus (DENV) NS1 early in dengue illness correlate with the development of dengue haemorrhagic fever and other severe associated diseases (Chung et al., 2006a) .
NS1 has also been identified as a candidate antigen for vaccine development (Costa et al., 2006 (Costa et al., , 2007 . Immunization with NS1 or passive administration of anti-NS1 mAbs can protect mice against a lethal virus challenge (Chung et al., 2006b) . Therefore, the identification of antigenic epitopes in NS1 will help to define correlations of immune protection and lead to a better understanding of WNV pathogenesis. Furthermore, NS1 epitope characterization will accelerate vaccine design and the development of immunodiagnostic reagents.
The diagnosis of WNV and associated diseases has long been a challenge, especially in the area of differential diagnosis. RT-PCR is able to differentiate closely related viruses, but this approach can only be applied to specimens containing circulating virus or viral RNA. Serological tests for WNV infection include the virus-neutralization test, the haemagglutination-inhibition test, ELISA and immunofluorescence assay (IFA) (Shi & Wong, 2003) . Among these tests, the virus-neutralization test is recognized as the 'gold standard'. Virus neutralization provides the highest specificity, but requires paired acute-and convalescent-phase serum specimens, and involves the manipulation of live virus, which requires a high level of biocontainment. The implementation of IFA as a diagnostic tool is also limited by biosafety concerns. ELISA has also been used to detect IgM antibodies that react with WNV antigens. However, each test is confounded by potential cross-reactivity with other members of the JEV serocomplex or other flaviviruses, which may affect the diagnostic outcome (Koraka et al., 2002; McLean et al., 2002; Williams et al., 2001) . This is especially true in geographical regions where several flaviviruses coexist (Kuno, 2003) . In a recent study, an epitopeblocking ELISA based on a WNV NS1-specific mAb was used to differentiate WNV from JEV infections in horses and to detect natural infections among vaccinated populations (Kitai et al., 2007) .
The aim of our study was to identify WNV-specific and/or JEV serocomplex-specific B-cell epitopes in NS1 using a panel of NS1-specific mAbs and murine antisera (polyclonal antibodies; pAbs). The epitope mapping described in this report will facilitate the development of diagnostic tests for the serological detection of WNV infection and will also provide valuable insight into the antigenic structure of NS1.
RESULTS

Production and characterization of mAbs against NS1
Recombinant WNV NS1 was expressed successfully in Sf 9 cells following infection with a recombinant baculovirus encoding WNV NS1. The recombinant NS1 was recognized by WNV-positive equine serum by Western blotting (WB) (data not shown).
Mice were immunized with recombinant WNV NS1 to generate NS1-specific mAbs. We established eight hybridoma cell lines producing mAbs that reacted strongly with recombinant NS1 by ELISA and native NS1 on WNV antigen slides by IFA (Table 1) . We further analysed these mAbs for reactivity with viruses related antigenically to WNV. mAbs 1C10, 3C7, 3D10 and 3F1 reacted with WNV, but did not react with JEV, DENV1-4, yellow fever virus (YFV) or tick-borne encephalitis virus (TBEV). In contrast, mAbs 4D1, 4D2, 4D6 and 5F8 recognized WNV and JEV, but did not recognize other non-JEV serocomplex flaviviruses (Table 1) .
Next, the heavy and light chains of each mAb were determined by using a Mouse MonoAb-ID (HRP) kit (Invitrogen). As shown in Table 1 , the NS1-reactive mAbs contained either an IgG1 or IgG2a heavy-chain subtype. With the exception of mAb 4D6, all mAbs used a l light chain. The titres of antibodies secreted into culture supernatant and ascites fluid were measured by indirect ELISA. Antibody titres in culture supernatants ranged from 1 : 64 to 1 : 512, and titres in ascites fluids ranged from 1 : 64 000 to 1 : 512 000 (Table 1) .
Identification of B-cell epitopes in NS1 using NS1-specific mAbs A set of 35 peptides that covered the entirety of the WNV NS1 were expressed as fusion proteins with maltosebinding protein (MBP). Each peptide consisted of 16 aa and overlapped with the neighbouring peptides by 6 aa to ensure the maintenance of linear epitopes in the peptide series. The binding of eight NS1-specific mAbs to the peptide series was evaluated by ELISA. As shown in Table  2 , we found that each mAb recognized a different peptide from the series, indicating the presence of at least eight unique linear B-cell epitopes located throughout the WNV NS1.
Comprehensive mapping of linear B-cell epitopes in NS1 using pAbs from immunized mice
To identify linear epitopes within the WNV NS1 that were not identified in the screen using NS1-specific mAbs, we screened the aforementioned NS1 peptide series using pAbs from mice immunized with purified WNV NS1. As shown in Fig. 1 , 12 peptides in the series were recognized by pAbs from NS1-immunized mice. Eight of the 12 peptides recognized by murine pAbs were also recognized by an NS1-specific mAb (Table 2) , whilst the remaining four peptides represented newly identified linear epitopes targeted by mouse antibody responses. In summary, these data demonstrate that the WNV NS1 contains at least 12 independent linear B-cell epitopes that are targeted by mammalian antibody responses. The negative mouse sera did not react with the 35 MBP-fused polypeptides or MBP tag only (data not shown).
Identification of WNV-and JEV serocomplexspecific B-cell epitopes in NS1
We next investigated whether the linear epitopes in the WNV NS1 were conserved among viruses of the JEV serocomplex and other antigenically related flaviviruses. To this end, we aligned NS1 amino acid sequences from JEV serocomplex viruses and related flaviviruses to identify the sequences corresponding to linear epitopes identified in WNV NS1. These polypeptides were synthesized and subsequently used to evaluate cross-reactivity with WNV NS1-specific mAbs and pAbs from mice immunized with NS1.
Four WNV NS1-specific mAbs were determined to react with antigenic determinants found only in WNV (including Kunjin virus), and did not react substantially with peptides derived from other viruses of the JEV serocomplex (Fig. 2b, d , f and g), and were located at positions NS1-3 (aa 21-36), NS1-11 (aa 101-116), and NS1-27 (aa 261-276), respectively. In contrast, another four NS1-specific mAbs, which were located at positions NS1-1 (aa 1-16), NS1-4 (aa 31-46), NS1-14 (aa 131-146) and NS1-31 (aa 301-316), reacted with polypeptides derived from other viruses of the JEV serocomplex (Fig. 2a , c, e and h), indicating that these antigenic epitopes were conserved among many JEV serocomplex members. In summary, our screen of linear B-cell epitopes in WNV NS1 using mAbs revealed two groups of epitopes: members of the first group are specific to WNV NS1, and the second group of epitopes are conserved among viruses of the JEV serocomplex.
As depicted above, all WNV NS1 epitopes were also identified using pAbs from mice immunized with WNV NS1. The corresponding polypeptide sequences of NS1 of the JEV serocomplex members were identified and screened by ELISA for cross-reactivity with murine pAbs. The epitopes located at positions NS1-11 (aa 101-116), (Fig. 2d and f) and NS1-24 (aa 231-246) (Fig. 3c ) of WNV NS1 were determined to be specific to WNV, as pAbs did not react with polypeptides derived from the JEV serocomplex members SLEV, MVEV or JEV. The other nine epitopes were JEV serocomplex-specific antigenic determinants, as pAbs also recognized homologous polypeptides derived from MVEV, JEV and SLEV (Fig. 2a, b, c, e, g and h; Fig. 3a, b and d) . From these data, we found two regions that had different reactivity with mAbs and pAbs, located at positions NS1-3 (aa 21-36) and NS1-27 (aa 261-276). 
DISCUSSION
Antibodies are effective lines of defence in preventing and treating infectious diseases. Antibodies bind specific sites in an antigen, called epitopes, and contribute to immunity to viruses in several ways, including virus neutralization and opsonization. The development of mAbs and definition of epitopes are important to understand the antigenic composition of viral proteins and virus-antibody interactions at a molecular level. Further, mAbs with defined epitopes provide a foundation for epitope-based marker vaccine design and clinical application, and also provide a powerful research tool to study protein structure and to diagnose or control a variety of infectious agents (Denisova et al., 2008; Levy et al., 2007; May et al., 2005; Shen et al., 2009; Sukupolvi-Petty et al., 2010) .
NS1 is an important non-structural protein of flaviviruses. Studies show that passive administration of mAbs against NS1 or active immunization with NS1 gene/protein confers protection from lethal flavivirus challenge (Amorim et al., 2010; Chung et al., 2006b; Lin et al., 1998; Lin et al., 2008; Xu et al., 2004) , suggesting that immune responses targeted against NS1 play important roles in conferring immune protection. Precise mapping of epitopes in NS1 is important for understanding antibody-mediated protection and developing epitope-based marker vaccines and diagnostic tools. Some works have been done previously to map antigenic epitopes in NS1 of DENV (Chen et al., 2010; Huang et al., 1999; Jiang et al., 2010; Wu et al., 2001) , TBEV (Volpina et al., 2005) and JEV (Wang et al., 2009 ). In the case of WNV, however, epitope mapping has been focused mainly on the viral envelope glycoprotein (Kanai et al., 2006; Oliphant et al., 2006) . Chung et al. (2006b) mapped epitopes of NS1 by performing competitive binding assays and expressing truncated NS1 on the surface of yeast (Saccharomyces cerevisiae) and in bacteria, and mapped 21 of the newly generated mAbs to three NS1 fragments. Further experiments confirmed that some of them conferred strong protection against lethal WNV infection. However, they only identified the relative regions in WNV NS1 recognized by the mAbs, and did not perform fine mapping of the epitopes. To our knowledge, there has been no report of linear epitope mapping of the WNV NS1.
In this study, we used a panel of well-characterized mAbs directed against NS1 and murine pAbs to comprehensively map linear B-cell epitopes in WNV NS1 against a series of NS1-derived polypeptides. NS1-specific mAbs were used to identify eight linear B-cell epitopes in WNV NS1. Using only mAbs to identify NS1 B-cell epitopes may miss some epitopes targeted by mammalian antibody responses; therefore, we additionally generated pAbs from mice immunized with recombinant NS1, and used the pAbs to screen an NS1 peptide series for linear epitopes. This approach identified four additional NS1 B-cell epitopes, and also confirmed the identity of the eight epitopes identified using the mAbs.
We experimentally evaluated the conservation of the identified epitopes among the JEV serocomplex viruses, and classified epitopes as either WNV-specific or JEV serocomplex cross-reactive. Five novel WNV-specific B-cell epitopes were identified in these studies (four of them were identified by using mAbs and three by using pAbs, but two of them were in the same regions, located at aa 101-116 and 191-206) . Alignment of amino acid sequences from all WNV isolates, including Kunjin virus, indicated that WNV-specific B-cell epitopes are highly conserved among WNV strains. In addition, using pAbs we identified nine epitopes that were conserved among the JEV serocomplex members. These JEV serocomplex-specific B-cell epitopes were associated with NS1-1, -3, -4, -7, -14, -23, -26, -27 and -31 (located at aa 1-16, 21-36, 31-46, 61-76, 131-146, 221-236, 251-266, 261-276 and 301-316, respectively) . However, the epitope located at aa 261-276 in SLEV had no reaction with pAbs by ELISA; maybe one or a few critical amino acid mutation(s) has an influence on the epitope's reactivity. Importantly, the epitopes located at positions NS1-3 (aa 21-36) and NS1-27 (aa 261-276) have different reactivity with corresponding mAbs and pAbs, so we think that these two regions might contain at least two different epitopes. Additionally, identification of the 
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YFV-NS1 FJ654700 E.-C. Sun and others specificity of the epitopes was repeated by WB through expressed MBP-fused polypeptides; the results are coincident with those obtained by ELISA except for peptide NS1-7 from SLEV (data not shown). This peptide did not react with pAbs by WB; the reasons for this remain to be determined. Although we used many polypeptides to identify the specificity of each epitope, the amino acid mutations in NS1 from associated flaviviruses are widespread (Sotelo et al., 2009) , so it would not be practical to test every possible epitope. However, some variant epitopes within other JEV genotypes were tested for the following positions: NS1 aa 8 (IAV mutation), aa 193 (TAA), aa 198 (VAL), aa 261 (KAM), aa 271 (IAK) and aa 315 (NAS), and no additional differences were seen (data not shown). Another important point is that NS1 from WNV and JEV exists as two forms: NS1 and NS19. NS19 is a longer version derived from translation of an alternative reading frame induced by a frameshift towards the 39 end of the NS1 gene. It is an NS1-2A-related protein of about 56 kDa, is often observed in JEV-infected cells (Mason, 1989) and is presumably generated by a protease that recognizes an alternative cleavage site within NS2A (Jan et al., 1995) . In our experiments we focused on NS1, not NS19, maybe resulting in some omissions that will need further investigation.
T T E S G K L I T
Cross-reactivity among flaviviruses has been a diagnostic challenge for members of the JEV serocomplex, among which differentiation is often difficult, even using the 'gold standard' neutralization test (McLean et al., 2002) . This is largely due to the fact that the E glycoprotein of JEV serocomplex members contains highly conserved immunodominant epitopes that elicit cross-reactive serum antibodies during infection (Oliphant et al., 2006) . Thus, the identification of WNV-specific mAbs and epitopes in NS1 is important and has great potential for future improvement of WNV serological diagnosis and the development of epitope-based marker or subunit vaccines.
METHODS
Cell lines, plasmids, serum specimen and viruses. The myeloma cell line SP2/0 (maintained in our laboratory) was cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) in a humidified 5 % CO 2 atmosphere at 37 uC. Spodoptera frugiperda (Sf 9) cells were cultured in Grace's insect medium (Gibco Invitrogen) at 28 uC. All culture media were supplemented with 10 % heatinactivated FBS (Gibco Invitrogen), 0.1 mg streptomycin ml 21 and 100 IU penicillin ml 21 . The sequence encoding NS1 of the WNV NY99 genome (GenBank accession no. AY842931) cloned into plasmid pMAL-C2x (New England Biolabs) and components of the Bac-to-Bac baculovirus expression system (Invitrogen) were maintained in our laboratory. The WNV-positive equine serum was from the CSIRO Australian Animal Health Laboratory. The flavivirus strains (DENV1, D1-ZJ-57; DENV2, D2-43; DENV3, D3-80-2; DENV4, D4-B5; JEV, SA-14-14-2, GenBank AF315119.1; TBEV, Senzhang, GenBank AY182009.1; WNV, Chin-01, GenBank AY490240.2; and YFV, 17D/Tiantan, GenBank FJ654700.1) used in this study were obtained from the Beijing Institute of Microbiology and Epidemiology, PR China.
Expression of recombinant NS1. Recombinant WNV NS1 was prepared according to the product instructions of the Bac-to-Bac baculovirus expression system (Invitrogen). In brief, the NS1 gene from WNV NY99 strain was cloned into the pFastBac vector. The recombinant pFastBac vector was then transformed into competent DH10Bac Escherichia coli cells, which were subsequently plated on triple-antibiotic LB plates (kanamycin, gentamicin and tetracycline) with BluoGal (Sigma). The site-specific transposition reaction takes place between the mini-Tn7 elements (pFastBac vector) and the miniattTn7 attachment sites on the bacmid DNA in DH10Bac. This reaction is mediated by a transposase, an enzyme encoded by the helper plasmid that is also in DH10Bac E. coli. The transposition step disrupts the lacZ reading frame and allows blue/white screening. Colonies containing the recombinant bacmid DNA appear white, whereas colonies containing the non-recombinant bacmid DNA appear blue. Bacmid DNA was recovered from white colonies and was subsequently verified via PCR. Insect cells were transfected with recombinant Bacmid DNA by using Cellfectin (Invitrogen). Recombinant baculovirus supernatant was harvested 2-5 days after transfection and titrated using a BaculoTiter Assay kit (Invitrogen) according to the manufacturer's instructions. Recombinant protein was analysed by SDS-PAGE and purified by Ni-NTA affinity chromatography (Qiagen) according to the manufacturer's instructions, then identified by WB (Sun et al., 2011) . For WB, recombinant NS1 and Sf 9 cells infected with wild-type baculovirus were subjected to SDS-PAGE (10 % gel) after reduction with DTT at 100 uC for 5 min. Samples were transferred to a nitrocellulose membrane and were blocked overnight with 5 % skimmed milk powder in PBS with 0.05 % Tween 20 (Sigma) (PBST) at 4 uC. The membrane was incubated with WNV-positive equine sera as the primary antibody at a 1006 dilution, followed by an HRP-conjugated rabbit anti-equine secondary antibody at a 40006 dilution (LICOR Biosciences). The colour was developed using 3,39-diaminobenzidine tetrahydrochloride (DAB) substrate and was stopped by rinsing in deionized water followed by drying the membrane.
Production of murine pAbs. BALB/c mice (6 weeks old) were immunized subcutaneously with purified recombinant NS1 in Freund's complete adjuvant (Sigma). Mice received two booster immunizations with NS1 in Freund's incomplete adjuvant at 2 week intervals. Two weeks after the final booster, the sera were collected and used for the experiments described in this report.
Preparation and characterization of mAbs against NS1.
Hybridoma cells secreting NS1 protein-specific antibodies were Fig. 3 . Assessment of murine pAb recognition of another four epitopes from homologous regions of viruses from the JEV serocomplex. Murine pAbs from mice immunized with WNV NS1 were tested for reactivity against four corresponding polypeptides from other JEV serocomplex viruses by ELISA to identify serotype-and group-specific B-cell epitopes. For each polypeptide, the left panel displays the results of the ELISA evaluating antibody binding to the JEV serocomplex peptides. Each bar indicates pAb reactivity as determined by the mean A 492 . The right panels depict the sequence alignments used to identify corresponding polypeptide sequences from representative strains of associated flavivirus isolates. The sequences from DENV1-4 and YFV are shown only for comparison. generated according to standard procedures with a few modifications (Köhler & Milstein, 1975) . Briefly, an additional four 6-week-old female BALB/c mice were immunized subcutaneously as described above with one additional intraperitoneal immunization without adjuvant. Three days after the final dose, mice were euthanized and spleen cells were harvested and fused with SP2/0 myeloma cells at a ratio of 5-10 : 1 using polyethylene glycol (PEG 4000; Sigma). The hybridoma cells were seeded into 96-well plates and selected in HAT medium (DMEM containing 20 % FBS, 100 mg streptomycin ml 21 , 100 IU penicillin ml 21 , 100 mM hypoxanthine, 16 mM thymidine and 400 mM aminopterin) and, after 5 days, the medium was removed and replaced with fresh HT medium (HAT medium lacking aminopterin). After HAT/HT selection, culture supernatants of surviving clones were screened for reactivity and specificity by indirect ELISA, WB and IFA. The ELISA has been described previously (Konishi et al., 2001) . Briefly, microplates were sensitized at 4 uC overnight with the affinity-purified WNV NS1 at 100 ng ml
21
. The sensitized plates were incubated with test culture supernatants from hybridoma cells at 37 uC for 1 h, with HRP-conjugated goat anti-mouse secondary antibodies (LICOR Biosciences) at a 1 : 4000 dilution at 37 uC for 1 h, followed by colour development with substrate solution containing o-phenylenediamine. Development was stopped with 2 M H 2 SO 4 .
WB was performed using mAb supernatants as primary antibodies and an HRP-conjugated goat anti-mouse secondary antibody.
The IFA results were supplied by the Beijing Institute of Microbiology and Epidemiology. WNV, JEV, DENV1-4, YFV and TBEV antigens were prepared on porous slides using both virus-infected and uninfected cells. Cell suspensions were dripped directly onto slides, fixed using acetone, air-dried and stored at 220 uC. Next, anti-NS1 mAb original supernatant and WNV-, JEV-, DENV1-4-, YFVand TBEV-positive/negative murine sera (positive/negative control; working dilution was 1 : 100) were incubated on acetone-fixed antigen slides for 2 h. An FITC-conjugated goat anti-mouse IgG was used as a secondary antibody at a 1 : 50 dilution, and slides were viewed at a magnification of 640 on a fluorescence microscope (Leica).
Positive clones were subcloned three times by limiting dilution. Selected clones were cultured in the peritoneal cavities of pristane (Sigma)-primed BALB/c mice to obtain ascites fluid.
The mAb titre was determined by indirect ELISA as described above and the antibody subtype was determined using a Mouse MonoAb-ID (HRP) kit (Invitrogen) according to the manufacturer's instructions. This test identifies the IgG1, IgG2a, IgG2b, IgG3, IgA and IgM subtype classes and the k and l light chains using monospecific rabbit pAbs.
Polypeptide design and expression. A panel of 35 peptides (named NS1-1 to NS1-35), spanning the entirety of the NS1, were designed such that adjacent peptides had six amino acid residues in common, i.e. peptide NS1-1 corresponded to aa 1-16, peptide NS1-2 corresponded to aa 11-26, and so on. To express these polypeptides, we synthesized complementary oligonucleotide pairs encoding each peptide (see Supplementary Table S1 , available in JGV Online), annealed and cloned them into the EcoRI and SalI sites of pMAL M -C2x, which included an in-frame MBP tag, to generate 35 recombinant plasmids. The recombinant plasmids were transformed into E. coli TB1 cells (TaKaRa) for expression. Transformed cells were grown in rich medium (for 1 l: 10 g tryptone, 5 g yeast extract, 5 g NaCl, 2 g glucose; autoclave; add sterile ampicillin to 100 g ml 21 ) to an OD 600 of approximately 0.5-0.7. A final concentration of 0.5 mM IPTG (Pharmacia Biosciences) was added to induce recombinant protein expression and the cells were agitated for an additional 10 h at 16 uC. Bacteria were pelleted at 9000 g for 10 min at 4 uC and lysed by sonication in column buffer (20 mM Tris/HCl, 200 mM NaCl, 1 mM EDTA). SDS-PAGE was carried out to characterize the production of each MBP-fused recombinant polypeptide.
Epitope mapping using mAbs and pAbs. The MBP-fused polypeptides were expressed and screened by indirect ELISA using mAbs, and by WB using pAbs. The ELISA was performed as described above, using the expressed MBP-fused polypeptides as coating antigen. MBP tag was used as protein control, and murine negative sera were used as negative control.
For WB, briefly, the expressed MBP-fused polypeptides (NS1-1 to NS1-35) and MBP tag alone were subjected to SDS-PAGE (10 % gel) after reduction with DTT at 100 uC for 5 min. The protein was transferred onto a nitrocellulose membrane and blocked with 5 % skimmed milk powder in PBST overnight at 4 uC. The membranes were incubated with murine pAbs/negative sera as the primary antibody at a 1 : 1000 dilution and, subsequently, an HRP-conjugated goat anti-mouse secondary antibody (LICOR Biosciences). The colour was developed using DAB and the reaction was stopped by rinsing in deionized water followed by drying the membrane.
Analysis of cross-reactivity using polypeptides from NS1 of other JEV serocomplex viruses. Amino acid alignments were performed between the identified WNV NS1 epitopes and other flaviviruses, including the JEV serocomplex members Kunjin virus, JEV, SLEV and MVEV, and other antigenically related flaviviruses, DENV1-4 and YFV, using Lasergene (DNASTAR Inc.). Based on the amino acid alignments, polypeptides of homologous regions in NS1 of JEV serocomplex viruses were synthesized (see Supplementary  Table S2 , available in JGV Online) (Shanghai Bootech BioScience and Technology). The synthesized polypeptides were evaluated for reactivity with each mAb and pAb by ELISA. The irrelevant peptide control was V5 tag (GKPIPNPLLGLDST), and murine negative sera were used as negative controls. A positive/negative value ¢2.1 was considered a positive result.
The polypeptide sequences chosen were the predominant amino acid residues at each position according to the alignment results using all available strains of each virus in the NCBI Entrez protein database (http://www.ncbi.nlm.nih.gov/protein/).
WNV-specific epitope alignment. To investigate the homology of the five WNV-specific epitopes among different WNV strains (including Kunjin virus strains), sequence alignments between each identified epitope and the fragments from the homologous region of other WNV strains was completed by using the EBI protein database (http://www.ebi.ac.uk/Tools/blast2/).
